Primate models of Parkinson's disease

By Collier T.J.   Steece-Collier K.   Kordower J.H.  

Experimental Neurology, Vol. 183, Iss. 2, 2003-10 ,pp. : 258-262

Elsevier

Access to resources Recommend Favorite

- and -Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease

By Henry B.   Fox S.H.   Crossman A.R.   Brotchie J.M.  

Experimental Neurology, Vol. 171, Iss. 1, 2001-09 ,pp. : 139-146

Elsevier

Access to resources Recommend Favorite

Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia

By Ravenscroft P.   Chalon S.   Brotchie J.M.   Crossman A.R.  

Experimental Neurology, Vol. 185, Iss. 1, 2004-01 ,pp. : 36-46

Elsevier

Access to resources Recommend Favorite

Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease

By Nash J.E.   Fox S.H.   Henry B.   Hill M.P.   Peggs D.   McGuire S.   Maneuf Y.   Hille C.   Brotchie J.M.   Crossman A.R.  

Experimental Neurology, Vol. 165, Iss. 1, 2000-09 ,pp. : 136-142

Elsevier

Access to resources Recommend Favorite

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease

By Merims D.   Shabtai H.   Korczyn A. D.   Peretz C.   Weizman N.   Giladi N.  

Journal of Neural Transmission, Vol. 111, Iss. 10-11, 2004-10 ,pp. : 1447-1453

Springer Publishing Company

Access to resources Recommend Favorite